I'm LongbridgeAI, I can summarize articles.Contineum Therapeutics updated its corporate presentation, highlighting PIPE-791 as the lead program with ongoing Phase 2 trials for IPF and favorable Phase 1 safety data. The company also detailed the PIPE-307 partnership with Janssen. Additionally, Contineum projects its cash runway extends through mid-2029, reflecting disciplined capital allocation.
Contineum Therapeutics updated its corporate presentation to highlight PIPE-791 clinical progress, PIPE-307 partnership details and a projected cash runway through mid-2029.
Key Highlights:
- Updated corporate presentation (Exhibit 99.1) posted to company website; future updates will be posted online, not via 8-K filings.
- PIPE-791 presented as lead program: brain-penetrant LPAR1 antagonist with Phase 2 global IPF trial underway; estimated completion June 2028.
- PIPE-791 shows favorable Phase 1 safety, >90% receptor occupancy at low doses and positive Phase 1B chronic pain signals, supporting further development.
- PIPE-307 (JNJ-5120) M1R antagonist developed by Janssen; Janssen retains sole discretion to develop for MDD or other indications.
- Presentation notes disciplined capital allocation and projects existing cash and equivalents to fund operations through mid-2029.
Original SEC Filing: Contineum Therapeutics, Inc. [ CTNM ] - 8-K - Jul. 13, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.